cleminorexton

Cleminorexton (formerly ORX750) is an orally active, small molecule **orexin receptor 2 (OX2R) agonist** developed by Centessa Pharmaceuticals (acquired by Eli Lilly). It is designed to address the neurobiological system critical to the sleep-wake cycle, specifically targeting the deficiency or dysfunction of orexin signaling associated with sleep-wake disorders. The drug has demonstrated a potential best-in-class profile in Phase 2a clinical studies, showing significant efficacy in treating excessive daytime sleepiness across **narcolepsy type 1 (NT1)**, **narcolepsy type 2 (NT2)**, and **idiopathic hypersomnia (IH)**. Beyond these primary indications, cleminorexton is being explored for its potential utility in broader neurological, neurodegenerative, and neuropsychiatric conditions where wakefulness and arousal systems are impaired.

Other names

cleminorexton